Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Isofol Medical AB (ISOFOL) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Isofol Medical AB SEK 0.29, price SEK 0.81, upside -64.3%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
IM
Thin data
Sep 24, 2026
Isofol Medical AB
ISOFOL · STWeakest SetupStrongly overvalued and low quality.
!Fair value kr 0.2890 · Strongly overvalued (−64%)
!Quality 38/100
!Weak Growth (revenue 3y −73.1 %/yr)
!negative free cash flow
!Trails peers (2/6)
!Narrow moat 8/100
!Insider activity 35/100
!Evidence only low, so the estimate is less certain
Watch Isofol Medical AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 0.4915 – kr 14.18 · fair‑value band kr 0.1870 – kr 0.3570 · the kr 0.8100 price screens above the kr 0.2890 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Isofol Medical in your weekly email
Every Wednesday you see whether Isofol Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
Stock analysis
Isofol Medical AB (ISOFOL) currently trades at kr 0.8100, while our model-based Fair Value estimate is kr 0.2890, implying the stock looks roughly 180.3% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.1870 (bear) to kr 0.3570 (bull), the price of kr 0.8100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Isofol Medical AB reported revenue of 0 SEK in FY2025 versus 22.4M SEK in FY2021. Reported net income was −54.2M SEK in FY2025.
Key figures
Market cap 249M SEK (≈ $25.1M) · EPS (TTM) kr −0.2200 · Return on equity −70.7% · Return on assets (EBIT) −49.9% · Free cash flow −51.9M SEK · Net cash 42.0M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −64%, ISOFOL screens richer than that median.
Fair Value models
Bear kr 0.1870
Fair Value kr 0.2890
Bull kr 0.3570
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
kr 0.1700
kr 0.2300
kr 0.3400
51
All 1 models by family
Asset-Based
NCAV (Graham)
kr 0.1700
kr 0.2300
kr 0.3400
51
Notify me when ISOFOL reaches fair value
Put ISOFOL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
38/100
Of which business quality 41 · Market factors (momentum, volatility) 50
Profitability
0
Margins and returns on capital today
Quality Growth
62
Are margins and returns improving?
Cashflow
31
Earnings quality: real cash, not paper profit
Fin. Strength
75
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
35
Calm price path (market factor)
Momentum
59
Price trend over the last 3–12 months (market factor)
52W Momentum
54
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−94.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.1%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
’15
’16
’17
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−31,976.7% (2017) → −5,781.3% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
ISOFOL screens 180% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Compare Isofol Medical AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $514.99 | $566.49 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $803.90 | $1,252 | +56% |
| argenx SE ARGX | $963.79 | $918.60 | −5% |
| Samsung Biologics Co 207940 | 1,366,000 KRW | 1,502,600 KRW | +10% |
| CSL Limited CSL | A$179.24 | A$197.16 | +10% |
| Alnylam Pharmaceuticals, Inc ALNY | $251.65 | $218.36 | −13% |
| Royalty Pharma plc RPRX | $58.52 | $24.22 | −59% |
| BeOne Medicines AG 6160 | HK$218.20 | HK$169.72 | −22% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| BioNTech SE BNTX | $100.87 | $63.62 | −37% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Isofol Medical AB (ISOFOL) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.2890 versus a price of kr 0.8100, about −64% upside (overvalued).
What is the fair value of ISOFOL?
Our model-based fair value for Isofol Medical AB is kr 0.2890 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 0.8100.
What is the quality score of ISOFOL?
Isofol Medical AB has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Isofol Medical AB (ISOFOL)?
Our model-based price target is the fair value of kr 0.2890 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. It is a calculation from audited fundamentals, not an analyst target.
What is the Isofol Medical AB stock forecast for 2026?
Our models put fair value at kr 0.2890, about −64% upside versus a price of kr 0.8100 (overvalued). Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Isofol Medical AB (ISOFOL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Isofol Medical AB it is kr 0.2890 per share (as of Sep 24, 2026), against a price of kr 0.8100. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Isofol Medical AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ISOFOL trades above its calculated fair value: price kr 0.8100, fair value kr 0.2890, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ISOFOL?
No. The price is what the market pays today (kr 0.8100); the fair value is what the company's own numbers justify (kr 0.2890). For Isofol Medical AB the two are kr 0.5210 per share apart. That gap is exactly why we show both numbers side by side.
How much is Isofol Medical AB worth?
The market values Isofol Medical AB at about 249M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 0.8100; our models calculate a fair value of kr 0.2890 per share.
What do the bullish and bearish scenarios say about ISOFOL?
Our models span a range for Isofol Medical AB: cautious scenario kr 0.1870, base kr 0.2890, optimistic kr 0.3570 per share (as of Sep 24, 2026, price kr 0.8100). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Isofol Medical AB (ISOFOL)?
Balance-sheet figures for Isofol Medical AB (as of Sep 24, 2026): return on equity −70.7%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ISOFOL from its 52-week high?
Isofol Medical AB trades at kr 0.8100, about 9% below its 52-week high of kr 0.8930 and 40% above the low of kr 0.5800 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2890 is for.
Which stocks are comparable to Isofol Medical AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Isofol Medical AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 0.8100, calculated fair value kr 0.2890 (−64%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ISOFOL calculated?
We run Isofol Medical AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.2890, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Isofol Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Isofol Medical AB (ISOFOL)?
The closing price on Sep 23, 2026 was kr 0.8100. Our model-based fair value is kr 0.2890, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Isofol Medical AB right now?
The price sits above even our optimistic bull case (kr 0.3570). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1870 to kr 0.3570) leaves room in how you read the outcome.
Key figures of Isofol Medical AB
How large is the market capitalisation of Isofol Medical AB (ISOFOL)?
The market capitalisation of Isofol Medical AB is 249M SEK (≈ $25.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Isofol Medical AB (ISOFOL)?
Earnings per share at Isofol Medical AB are kr −0.2200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Isofol Medical AB (ISOFOL)?
The return on equity (ROE) of Isofol Medical AB is −70.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Isofol Medical AB (ISOFOL)?
On an EBIT basis the return on assets of Isofol Medical AB is −49.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Isofol Medical AB (ISOFOL) generate?
The free cash flow of Isofol Medical AB is −51.9M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Isofol Medical AB (ISOFOL) hold?
Isofol Medical AB holds more cash than debt, 42.0M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Isofol Medical AB in the live analysis
One click puts Isofol Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.